19 Mar

Analysts Reduce Pfizer’s Target Price in March

WRITTEN BY Margaret Patrick

Analysts’ recommendations and target price

Wall Street analysts expect a potential upside of 5.57% for Pfizer (PFE) based on the company’s closing price on March 18. In 2019, analysts have already revised the company’s target price downward twice, from $45.35 in January to $44.46 in February and then to $44.14 in March.

Analysts’ current consensus recommendation for PFE is a “hold.” To know more about Pfizer’s growth drivers, read What Are the Key Growth Drivers for Pfizer in Fiscal 2019?

Analysts Reduce Pfizer’s Target Price in March

Of the 15 analysts covering Pfizer, two have given it “strong buys,” five have given it “buys,” seven have given it “holds,” and only one has given it a “sell.” The highest target price estimate for Pfizer is $53, and the lowest is $35, which implies significant volatility in analysts’ estimates.

On March 18, Pfizer closed at $41.81, 0.07% higher than its previous closing price, 21.82% higher than its 52-week low of $34.32, and 10.03% lower than its 52-week high of $46.47. The company’s market cap is $242.12 billion.

Based on its closing price on March 18, Pfizer has reported returns of 0.75% in the last week, -0.38% in the last month, and -6.19% in the last quarter. The company has reported returns of -2.43% in the last half year, 14.30% in the last year, and -4.22% year-to-date.

Revenue and EPS estimates

Analysts expect Pfizer’s revenue to see YoY (year-over-year) changes of 0.59% to $12.98 billion in the first quarter, -0.53% to $13.39 billion in the second quarter, -1.40% to $13.11 billion in the third quarter, and -1.96% to $13.7 billion in the fourth quarter of 2019. Analysts also expect Pfizer’s non-GAAP (generally accepted accounting principles) EPS to see YoY changes of -3.00% to $0.75 in the first quarter, -7.35% to $0.75 in the second quarter, -8.32% to $0.72 in the third quarter, and 5.61% to $0.68 in the fourth quarter.

Analysts expect Pfizer’s revenue to see YoY changes of -0.59% to $53.33 billion in 2019, 1.61% to $54.19 billion in 2020, and 4.56% to $56.66 billion in 2021. Analysts also expect Pfizer’s non-GAAP EPS to see YoY changes of -3.19% to $2.90 in 2019, 6.08% to $3.08 in 2020, and 10.06% to $3.39 in 2021.

Latest articles

President Trump eased the Huawei ban on June 28. Since then, investors have been closely monitoring how US officials implement the policy change.

22 Jul

Economic Data and Earnings Before the Fed's Meeting

WRITTEN BY Mohit Oberoi, CFA

Economic data and earnings will keep investors busy this week. More than a quarter of the S&P 500 companies are scheduled to release their earnings.

22 Jul

Why UPS's Q2 Earnings Could Fall Year-over-Year

WRITTEN BY Anirudha Bhagat

UPS is scheduled to report its second-quarter earnings results on July 24. Estimates suggest that things aren't looking good for it this quarter.

Boeing (BA) plans to report its second-quarter 2019 results on July 24.

Hershey (HSY) is set to report its second-quarter results on Thursday. We expect Hershey’s sales and earnings to grow year-over-year, but that growth to be low.

22 Jul

Align Technology: What to Expect in Q2

WRITTEN BY Margaret Patrick

Align Technology (ALGN) plans to release its second-quarter earnings on July 24 after the market closes.